マウスとミニブタにおける長期作用のグルコース反応性インスリン放出を誘発するポリ (bis (guanidinium) -オクサゾリン) -インスリン複合体
Haodong Zhang1, Qian Liang2, Weinan Jiang3
1State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
Journal of the American Chemical Society
|October 23, 2025
まとめ
この研究は,機能化されたポリマーを用いた新しいグルコース反応性インスリン製剤を提示しています. 新薬は糖尿病のミニブタの血糖値を 192 時間維持し,低血糖症を最小限に抑えるのに成功した.
科学分野:
- バイオマテリアル科学
- 内分泌学
- 薬物投与システム
背景:
- グルコース反応性のインスリン製剤は,天然のインスリン分泌を模倣することで,糖尿病の管理を改善することを目的としています.
- 制御不能なインスリン放出と潜在的低血糖現象が問題となっている.
- ポリマーとインスリン間の静電相互作用は,制御された放出の鍵です.
研究 の 目的:
- 皮膚下投与のための安全で効果的なグルコース反応性インスリン製剤を開発する.
- 既存の製剤のインスリン放出制限と低血糖症に対処する.
- インスリン投与の治療指数を増やすために
主な方法:
- リコンビネントヒトインスリンをビス・グアニニウム・機能化されたポリ・オクサゾリン・ポリマーに結合した配列を開発した.
- グルコース反応のためにフェニルボロン酸で改造されたポリマー
- 1型糖尿病のミニブタにおける配方生物適合性とインビボ性能の評価
主要な成果:
- 特殊な生物相容性を示した.
- 一回投与後に192時間持続した正常血糖値.
- 制御されたインスリン放出を示す軽微な低血糖症.
結論:
- ビス (グアニニウム) 機能化されたポリマーは,インスリン結合を効果的に強化し,無制御の放出を防止します.
- この戦略は,先進的なグルコース反応性インスリン製剤の開発に有望なアプローチを提供します.
- 開発された薬剤は,投与の負担を軽減した糖尿病治療の改善の可能性を示しています.
関連する概念動画
Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
Insulin Formulations: Types and Delivery
648
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
648
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581


